Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma

References

• Berglund A, Enblad G, Carlson K, Glimelius B, Hagberg H. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol 2000; 65: 17–22
   PubMed Web of Science ®Google Scholar
• Brice P, Simon D, Bouabdallah R, Belanger C, Haioun C, Thieblemont C, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000; 11: 1585–1590
   PubMed Web of Science ®Google Scholar
• Apostolidis J, Gupta R K, Grenzelias D, Johnson P W, Pappa V I, Summers K E, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527–536
   PubMed Web of Science ®Google Scholar
• Rohatiner A Z, Johnson P W, Price C G, Arnott S J, Amess J A, Norton A J, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177–1184
   PubMed Web of Science ®Google Scholar
• Schouten H C, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson H E, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927
   PubMed Web of Science ®Google Scholar
• Freedman A S, Neuberg D, Mauch P, Soiffer R J, Anderson K C, Fischer D C, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333
   PubMed Web of Science ®Google Scholar
• Horning S J, Negrin R S, Hoppe R T, Rossenberg S A, Chao N J, Long G D, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 404–409
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460–1468
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002; 100: 1141–1152
   PubMed Web of Science ®Google Scholar
• Bierman P J, Vose J M, Anderson J R, Bishop M R, Kessinger A, Armitage J O. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445–450
   PubMed Web of Science ®Google Scholar
• McCoy G A, Smith E P, Atkinson M E, Baranski B, Kahl B S, Juckett M, et al. A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: Long term experience with etoposide and thiotepa. Bone Marrow Transplantation 2004; 33: 19–24
   PubMed Web of Science ®Google Scholar
• Phase I-II studies with high-dose thiotepa and autologous marrow transplantation in patients with refractory malignancies, R H Herzig, J W Fay, G P Herzig. Wiley and Sons, New York 1987; 17–23
   Google Scholar
• Lazarus H M, Reed M D, Spitzer T R, Rabaa M S, Blumer J L. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 1987; 71: 689–695
   PubMedGoogle Scholar
• Jacobs P, King H S, Dent D M, Hayes M. VP-16-213 in the treatment of stage III and IV diffuse large cell lymphoma. Cancer 1985; 56: 1006–1013
   PubMed Web of Science ®Google Scholar
• Cervantes F, Reverter J C, Montserrat E, Rozman C. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine. Cancer Treat Rep 1986; 70: 665–667
   PubMedGoogle Scholar
• Wolff S N, Fer M F, McKay C M, Hande K R, Hainsworth J D, Greco F A. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: A phase I study. J Clin Oncol 1983; 1: 701–705
   PubMed Web of Science ®Google Scholar
• Giannone L, Wolff S N. Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation. Cancer Treat Rep 1987; 71: 759–761
   PubMedGoogle Scholar
• Finlay J L, August C, Packer R, Zimmerman R, Sutton L, Freid A, et al. High-dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignant astrocytomas of childhood and adolescence. J Neurooncol 1990; 9: 239–248
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fischer R I, Connors J M, , NCI Sponsored International Working Group, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Schiller J H, Ritch P S, Storer B, Trump D L. A pilot study of short-course, high-dose cytosine arabinoside, etoposide, and cisplatin in refractory, aggressive-histology, non-Hodgkin's lymphomas. Am J Clin Oncol 1989; 12: 502–506
   PubMed Web of Science ®Google Scholar
• Shipp M A, Neuberg D, Janicek M, Canellos G P, Shulman L N. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study. J Clin Oncol 1995; 13: 2916–2923
   PubMed Web of Science ®Google Scholar
• Hui S K, Das R K, Thomadsen B, Henderson D. CT-based analysis of dose homogeneity in total body irradiation using lateral beam. J Appl Clin Med Phys 2004; 5: 71–79
   PubMedGoogle Scholar
• Deconinck E, Foussard C, Milpied N, Betrand P, Michenet P, Cournillet-LeFebvre P, et al. High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS. Blood 2005
   Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, Forstpointneer R, Wandt H, Freund M, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667–2674
   PubMed Web of Science ®Google Scholar
• Sebban S, Belanger C, Brousse N, Mounier N, Brice P, Haioun C, , G.E.L.A. Study Group, et al. Comparison of CHVP + Interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 trial. Blood 2003; 102–104a, Abstract 354
   PubMed Web of Science ®Google Scholar
• Horning S J. Follicular lymphoma: Have we made any progress?. Ann Oncol 2000; 11(Suppl 1)23–27
   PubMed Web of Science ®Google Scholar
• Van Besien K, Loberiza, Jr F R, Bajorunaite R, Armitage J O, Bashey A, Burns L J, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Asuncion D J, Wolf C, Scott S, Territo M. Localized radiation increases morbidity and mortality after TBI-containing autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant 2003; 32: 863–867
   PubMed Web of Science ®Google Scholar
• Friedberg J W, Neuberg D, Monson E, Jallow H, Nadler L M, Freedman A S. The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2001; 7: 446–453
   PubMed Web of Science ®Google Scholar
• Press O W, Eary J F, Gooley T, Gopak A K, Liu S, Rojendran J G, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934–2942
   PubMed Web of Science ®Google Scholar
• Gopal A K, Rajendran J G, Petersdorf S H, Maloney D G, Eary J F, Woo B L, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158–3162
   PubMed Web of Science ®Google Scholar
• Gopal A K, Gooley T A, Maloney D G, Petersdorf S H, Sary J F, Rajendran J G, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis. Blood 2003; 102: 2351–2357
   PubMed Web of Science ®Google Scholar